PipelineReview. Business Intellegence Center

Antibodies

14 July 2014

New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice

10 July 2014

Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma

10 July 2014

Novartis announces NEJM publication of two phase III studies demonstrating high efficacy of secukinumab (AIN457) in psoriasis patients

10 July 2014

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

7 July 2014

Human Anti-human PD-1 Monoclonal Antibody “OPDIVO® Intravenous Infusion 20 mg/100 mg” Receives Manufacturing and Marketing Approval in Japan for the Treatment of Unresectable Melanoma

4 July 2014

Nippon Kayaku Announces Marketing Approval in Japan of Infliximab Biosimilar Monoclonal Antibody

3 July 2014

Glenmark’s Novel Monoclonal Antibody GBR 830 for Treatment of Autoimmune Diseases Entering Human Trials

3 July 2014

GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy

2 July 2014

AIMM Therapeutics’ Partner MedImmune Starts Clinical Studies with RSV Antibody

1 July 2014

Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU

1 July 2014

Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE® Antibody Blinatumomab In Acute Lymphoblastic Leukemia

1 July 2014

GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians’ choice for bulky fludarabine-refractory CLL

30 June 2014

Merck’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma

27 June 2014

CHMP recommends EU approval of Roche’s Avastin for platinum-resistant recurrent ovarian cancer

27 June 2014

Bayer Receives positive CHMP Opinion for the Treatment of Visual Impairment due to Diabetic Macular Edema in EU

26 June 2014

Boehringer Ingelheim’s Investigational Antidote for Pradaxa® (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation

25 June 2014

Announcement of Results from a Multiple Dose Phase 1/2 Study of a Human Monoclonal Anti-FGF23 Antibody (KRN23) in X-linked Hypophosphatemia in Adults

25 June 2014

Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early

24 June 2014

New Toxicology Study Demonstrates Decreased Mortality And Better Tolerability Of ADC Generated With SMARTag Platform Vs. Conventional Technology

23 June 2014

Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Rheumatoid Arthritis

20 June 2014

Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121

19 June 2014

MacroGenics Initiates Phase 1 Study of MGD006 for the Treatment of Acute Myeloid Leukemia

19 June 2014

OncoMed Provides Update on FZD8-Fc (OMP-54F28) Phase I Clinical Trials

18 June 2014

Kyowa Hakko Kirin initiates a Phase I Trial of KHK6640 for Alzheimer’s Disease in Europe

17 June 2014

Lilly Announces Detailed Results from Two Phase III Studies Testing Both Doses of Dulaglutide vs. Insulin Glargine

17 June 2014

ABLYNX’S ANTI-vWF NANOBODY, CAPLACIZUMAB, ACHIEVES CLINICAL PROOF-OF-CONCEPT IN PHASE II TITAN STUDY

16 June 2014

Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis

16 June 2014

ImmunoGen, Inc. Announces Preclinical Findings for IMGN779, a Potential Treatment for Acute Myeloid Leukemia

16 June 2014

Lilly’s Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial

14 June 2014

Vantictumab Placed on Partial Clinical Hold by FDA Following Voluntary Halt by OncoMed

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing
Claudin 6: A target opportunity to develop effector-enhanced drug modalities
Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective
DLL3-Targeted Immunotherapy Candidates Pipeline Review
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis
RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins